MX2019011252A - Anticuerpos anti-c5a y usos de los mismos. - Google Patents

Anticuerpos anti-c5a y usos de los mismos.

Info

Publication number
MX2019011252A
MX2019011252A MX2019011252A MX2019011252A MX2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A MX 2019011252 A MX2019011252 A MX 2019011252A
Authority
MX
Mexico
Prior art keywords
complement
antibody
individual
antibodies
relates
Prior art date
Application number
MX2019011252A
Other languages
English (en)
Inventor
Song Wenchao
Sato Sayaka
Miwa Takashi
Gullipalli Damodar
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2019011252A publication Critical patent/MX2019011252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a la inhibición de la señalización del complemento usando un anticuerpo anti-C5a; específicamente, la invención se refiere a métodos para tratar una enfermedad mediada por el complemento o trastorno mediado por el complemento en un individuo, poniendo en contacto al individuo con un anticuerpo anti-C5a.
MX2019011252A 2017-03-23 2018-03-23 Anticuerpos anti-c5a y usos de los mismos. MX2019011252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475573P 2017-03-23 2017-03-23
PCT/US2018/023927 WO2018175833A1 (en) 2017-03-23 2018-03-23 Anti-c5a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011252A true MX2019011252A (es) 2020-01-23

Family

ID=63585782

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011252A MX2019011252A (es) 2017-03-23 2018-03-23 Anticuerpos anti-c5a y usos de los mismos.

Country Status (13)

Country Link
US (2) US11274146B2 (es)
EP (1) EP3600421A4 (es)
JP (2) JP7251792B2 (es)
KR (1) KR20190132665A (es)
CN (1) CN110709101B (es)
AU (1) AU2018237300A1 (es)
BR (1) BR112019019595A2 (es)
CA (1) CA3057146A1 (es)
EA (1) EA201992248A1 (es)
IL (1) IL269428A (es)
MX (1) MX2019011252A (es)
SG (1) SG11201908744PA (es)
WO (1) WO2018175833A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048495A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
CA3055541A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pennsylvania Anti-c5 antibodies and uses thereof
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3846850A4 (en) 2018-09-06 2022-06-15 The Trustees of the University of Pennsylvania HUMANIZED ANTI-C5 ANTIBODIES AND THEIR USES
US20220332802A1 (en) * 2019-06-06 2022-10-20 Children's Hospital Medical Center Methods and compositions for treatment of neurodegeneration
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
EP3372243A1 (en) 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
KR20100117120A (ko) * 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
SG184452A1 (en) * 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
AU2011245117B2 (en) * 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
BR112012027994B1 (pt) * 2010-05-04 2021-10-13 Five Prime Therapeutics, Inc Anticorpo, composição farmacêutica e uso de um anticorpo
EP2608807A1 (en) 2010-08-27 2013-07-03 Stem Centrx, Inc. Notum protein modulators and methods of use
CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
MX354243B (es) * 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
EP2702412B1 (en) * 2011-04-28 2017-07-26 SBI Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase antibody
EP3974832A1 (en) * 2011-10-06 2022-03-30 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
EP3693389B1 (en) 2014-07-10 2024-09-04 Universität Zürich Immune-stimulating monoclonal antibodies against human interleukin-2
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA3055541A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pennsylvania Anti-c5 antibodies and uses thereof
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體

Also Published As

Publication number Publication date
BR112019019595A2 (pt) 2020-04-14
US20200148754A1 (en) 2020-05-14
US11274146B2 (en) 2022-03-15
RU2019133479A (ru) 2021-04-23
IL269428A (en) 2019-11-28
CN110709101A (zh) 2020-01-17
EP3600421A4 (en) 2021-01-06
AU2018237300A1 (en) 2019-10-17
CA3057146A1 (en) 2018-09-27
CN110709101B (zh) 2024-05-07
SG11201908744PA (en) 2019-10-30
EA201992248A1 (ru) 2020-02-06
KR20190132665A (ko) 2019-11-28
JP2022183224A (ja) 2022-12-08
RU2019133479A3 (es) 2021-11-24
JP2020511505A (ja) 2020-04-16
EP3600421A1 (en) 2020-02-05
WO2018175833A1 (en) 2018-09-27
JP7251792B2 (ja) 2023-04-04
US20220153824A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
ZA201905866B (en) Anti-c5 antibodies and uses thereof
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
PH12019502283A1 (en) Anti-lag3 antibodies
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2019014291A (es) Metodo de tratamiento.
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.